Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
While some get the jab faithfully each flu season, about half of the American population declines, likely over doubts of the vaccine’s effectiveness and necessity.
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study.
Autolus is currently working on advancing obecabtagene autoleucel, its CD19 CAR T cell investigational therapy product candidate, in addition to other applications of obe-cel in B-cell malignancies.
Researchers aren’t sure why the mRNA vaccines appear to cause myocarditis symptoms. The FDA said the risk appears more after the second dose. Find more here.
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
The $80 million infusions from ATP will advance Marengo’s lead candidate, STAR0602, which aims to treat advanced and metastatic solid tumors.
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
Mid-November is a relatively quiet period for the U.S. Food and Drug Administration in terms of its scheduled PDUFA dates. Read on for more.
The pharma industry is a very lucrative field to invest your efforts in. In this article, we will cover the reasons many people love working in the pharmaceutical industry.
Amgen plans on investing $365 million in the site, including the introduction of 400 new job openings through the operations of its pharmaceutical packaging and assembly facility.
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
Ardelyx, Inc. is lacing up the gloves and preparing to wade into the ring with the U.S. Food and Drug Administration to dispute the July rejection of its chronic kidney disease drug, tenapanor.